JRC Publications Repository

JRC Publications Repository >

Browsing by Author MORGENSTERN Alfred

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 59 to 78 of 136
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2013Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay seriesSULIMAN GABRIEL; POMME Stefaan; MAROULI Maria; VAN AMMEL Raf; STROH HEIKO; JOBBAGY Viktor; PAEPEN Jan; DIRICAN A.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos, et alArticles in Journals
2012High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneumRAUCH C; SEIDL C.; SCHLAPSCHY M; SKERRA A; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2013High Resolution microSPECT imaging of Bi-213DE SWART J; SEGBERS M; MORGENSTERN Alfred; VAN DER HAVE F; CHAN Ho-Sze; BERNDSEN S.c.; BRUCHERTSEIFER Frank; DE JONG Marion; BEEKMAN F.j.; KONIJNENBERG M.w.Contributions to Conferences
2012High-resolution alpha-particle spectrometry of the 230U decay seriesMAROULI MARIA; POMME Stefaan; PAEPEN Jan; VAN AMMEL Raf; JOBBAGY VIKTOR; DIRICAN ABDULLAH; SULIMAN GABRIEL; STROH HEIKO; APOSTOLIDIS Christos; ABBAS Kamel, et alContributions to Conferences
2010Immunoliposomal Delivery of 213Bi for Alpha-emitter Targeting of Metastatic Breast CancerLINGAPPA M.; SONG H.; THOMPSON S.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SGOUROS G.Articles in Journals
2007An Improved Method for the Production of Ac-225/Bi-213 from Th-229 for Targeted Alpha TherapyZIELINSKA Barbara; APOSTOLIDIS CHRISTOS; BRUCHERTSEIFER FRANK; MORGENSTERN ALFREDArticles in Journals
2009In vitro and in vivo comparison of 226Th and 213Bi-labelled radioconjugates for target alpha therapyBRUCHERTSEIFER Frank; MORGENSTERN Alfred; FRIESEN CLAUDIA; ROSCHER MAREIKE; MILTNER E.; PFOST B.; SENEKOWITSCH-SCHMIDTKE R.; ABBAS Kamel; APOSTOLIDIS ChristosContributions to Conferences
2012In vitro evaluation of alpha-particle emitter Ac-225 for somatostatin receptor radiotherapyGRAF Franziska; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER M.m.; KAINA B; SCHRECKENBERGER M; MIEDERER MatthiasContributions to Conferences
2006In Vitro Screening for Synergism of High-linear Energy Transfer 213Bi-radiotherapy with other Therapeutic Agents for the Treatment of B-cell Chronic Lymphocytic LeukemiaVANDENBULCKE K.; THIERENS H.; VOS F.d.; OFFNER F.; JANSSENS F.; PHILIPPE J.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; BACHER K.; DE GELDER V., et alArticles in Journals
2005In Vivo and In Vitro Inhibition of Pancreatic Cancer Growth by Targeted Alpha Therapy using 213Bi-CHX.A"-C595QU C.f.; SONG Y.j.; RIZVI S.m.a.; SMITH R.m.; PERKINS A.c.; MORGENSTERN ALFRED; BRECHBIEL M.; ALLEN Barry J.Articles in Journals
2009Inhibition ofMicrometastatic Prostate Cancer Cell Spread in Animal Models By 213BilabeledMultipleTargeted Alpha-RadioimmunoconjugatesLI Y.; SONG E.; ABBAS RIZVI S. M.; POWER C. A.; BERETOV J.; RAJA C.; COZZI P. J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; ALLEN B. J., et alArticles in Journals
2006Interaction of Radiolabeled Antibodies with Fungal Cells and Components of Immune System In Vitro and During Radioimmunotherapy of Experimental Fungal InfectionDADACHOVA E.; BRYAN R.a.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; ZHANG T.; MOADEL T.; CASADEVALL A.Articles in Journals
2007Interim Analysis of Toxicity and Response in Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaRAJA C.; GRAHAM P.; ABBAS RIZVI S. M.; SONG E.; GOLDSMITH H.; THOMPSON J.; BOSSERHOFF A.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; KEARSLEY J., et alArticles in Journals
2005Intralesional Targeted Alpha Therapy for Metastatic MelanomaALLEN Barry J.; RAJA C.; RIZVI S.m.a.; LI Y.; TSUI W.; GRAHAM P.; THOMPSON J.; REISFELD R.a.; KEARSLEY J.; MORGENSTERN ALFRED, et alArticles in Journals
2009Intravesical a-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude MicePFOST Birgit; SEIDI Christof; AUTENRIETH Michael; SAUR Dieter; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SCHWAIGER Markus; SENEKOWITSCH-SCHMIDTKE ReingardArticles in Journals
2010Investigation of Para-sulfonatocalix[n]arenes [n = 6, 8] as Potential Chelates for 230UMONTAVON Gilles; REPINC Urska; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; ABBAS Kamel; MORGENSTERN AlfredArticles in Journals
2010Investigation of para-sulfonatocalix[n]arenes [n = 6, 8] as potential chelates for 230U†MONTAVON Gilles; REPINC Urska; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; ABBAS Kamel; MORGENSTERN AlfredArticles in Journals
2012Is DTPA a good competing chelating agent for Th(IV) in human serum and suitable in targeted alpha therapy?LE DU Alicia; SABATIE-GEGOVA Andrea; MORGENSTERN Alfred; MONTAVON GillesArticles in Journals
2011Magnetic Memory Effect in a Transuranic Mononuclear ComplexMAGNANI Nicola; APOSTOLIDIS Christos; MORGENSTERN Alfred; COLINEAU Eric; GRIVEAU Jean-Christophe; BOLVIN Hélène; WALTER OLAF; CACIUFFO RobertoArticles in Journals
2011Magnetic Memory Effect in a Transuranic Mononuclear ComplexMAGNANI Nicola; APOSTOLIDIS Christos; MORGENSTERN Alfred; COLINEAU Eric; GRIVEAU Jean-Christophe; WALTER Olaf; CACIUFFO RobertoArticles in Journals
Showing results 59 to 78 of 136

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top